Methodology

The FemMap platform provides visualization of public domain data available in the information systems of SUS (Unified Health System), therefore, it does not concern private healthcare.

Cervical cancer control actions can (and should) be monitored through indicators previously established by the Quality Management Manual for Cytopathology Laboratories (2016) and the Technical Sheet of Indicators for Cervical Cancer Control Actions (2014), documents that guide the present methodology. Thus, the proposal is to present, in one place, various data that are dispersed across different public platforms.

The role of FemMap is to facilitate information visualization – including calculating indicators based on raw data and visually representing them in maps down to the municipal scale. Additionally, it offers a tool for searching nearby healthcare providers and a communication channel for those interested in the subject, such as medical professionals, nurses, patients, and managers of laboratories and healthcare services at different levels.

The platform is divided into sections:

  1. Tool for visualizing the following indicators:
    • Crude mortality rate from Cervical Cancer (ICD C53), obtained through the Online Mortality Atlas (INCA - Ministry of Health);
    • Percentage of HSIL, calculated using data available in the Cancer Information System - SISCAN (cervix and breast) - DATASUS;
    • Coverage of Pap smear tests, corresponding to the performance indicator "Proportion of women with cytopathological collection in Primary Healthcare," obtained from the Health Information System for Primary Care – Sisab;
    • HPV vaccination coverage (at age 15, in 2022), calculated based on data from the National Immunization Program Information System (SI-PNI/CGPNI/DEIDT/SVS/MS), available on DATASUS.
  2. Quality Panel: presents quality indicators for each laboratory registered as a SUS service provider, based on the Cancer Information System - SISCAN (cervix and breast) – DATASUS:
    • Displays the total number of exams (satisfactory/unsatisfactory/rejected), positive exams, and HSIL results;
    • Positivity index;
    • Percentage of high-grade squamous intraepithelial lesion (HSIL);
    • Percentage of unsatisfactory exams;
    • Percentage of atypical squamous cells of undetermined significance among altered exams (ASC/Altered);
    • Percentage of atypical squamous cells of undetermined significance among satisfactory exams (ASC/Satisfactory);
    • Ratio between atypical squamous cells of undetermined significance and squamous intraepithelial lesion (ASC/SIL);
    • Average exam release time (to be added in the future).
  3. Status of service provider laboratories:
    • In this section, service provider laboratories were geolocated and classified into three levels according to compliance with the quality indicators calculated in the previous panel:
      • Excellent: all indicators within reference values;
      • Fair: 3 to 5 indicators within reference values;
      • Poor: fewer than 3 indicators within reference values.
  4. Nearby services:

    In this section, service provider laboratories, as well as Primary Healthcare Units, were geolocated. Address information was obtained through the National Registry of Health Establishments (CNES). Thus, you can find the nearest service to you!

For more information about the methodology, contact us!